泌石通胶囊联合坦索罗辛治疗输尿管末端结石的疗效观察

Clinical observation of Mishitong Capsules combined with tamsulosin in treatment of distal ureteral stone

目的探讨泌石通胶囊联合坦索罗辛治疗输尿管末端结石的临床疗效。方法收集2015年2月—2017年2月在南阳市中心医院进行治疗的输尿管末端结石患者82例,根据用药的差别分为对照组(41例)和治疗组(41例)。对照组口服盐酸坦索罗辛缓释胶囊,0.4 mg/次,1次/d;治疗组在对照组的基础上口服泌石通胶囊,0.9 g/次,2次/d。两组均经过2周治疗。评价两组患者临床疗效,同时比较治疗前后两组患者最大尿流率、结石排出时间以及QOL和VAS评分差异。结果治疗后,对照组的临床总有效率为80.49%,显著低于治疗组的95.12%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者最大尿流率显著升高,同组比较差异具有统计学意义(P<0.05)。治疗后,治疗组患者最大尿流率、结石排出时间和排石率均明显好于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者QOL和VAS评分均明显下降,同组比较差异具有统计学意义(P<0.05);且治疗组比对照组降低更显著,两组比较差异具有统计学意义(P<0.05)。结论泌石通胶囊联合坦索罗辛治疗输尿管末端结石可有效减轻患者痛苦,提高患者生活质量,具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacy of Mishitong Capsules combined with tamsulosin in treatment of distal ureteral stone. Methods Patients （82 cases） with distal ureteral stone in Nanyang City Center Hospital from February 2015 to February 2017 were divided into control （41 cases） and treatment （41 cases） groups based on different treatments. Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 0.4 mg/time, once daily. Patients in the treatment group were po administered with Mishitong Capsules on the basis of the control group, 0.9 g/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the difference of maximum urinary flow rate, stone expulsion time, QOL and VAS scores in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 80.49%, which was significantly lower than 95.12% in the treatment groups, and there were differences between two groups （P 〈 0.05）. After treatment, the maximum urinary flow rate in two groups was significantly increased, and the difference was statistically significant in the same group （P 〈 0.05）. After treatment, the maximum urinary flow rate, stone expulsion time and rate in the treatment group were obviously better than those in the control group, with significant difference between two groups （P 〈 0.05）. After treatment, the QOL and VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. And the scores in the treatment group were obviously lower than those in the control group, with significant difference between two groups （P 〈 0.05）. Conclusion Mishitong Capsules combined with tamsulosin can effectively relieve the pain and improve the quality of life in treatment of distal ureteral stone, which has a certain clinical application value.